SCHEMBL1991503

SCHEMBL1991503

O=C(O)C1(C(=O)CO)CCCN1O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8342630 0.86
SCHEMBL2544922 0.82 SLC18A3 (0.32)
SCHEMBL10484700 0.79 FFAR3 (0.32)
SCHEMBL28200533 0.76 CYP2C19 (0.33)
SCHEMBL1984087 0.75 FFAR3 (0.32)
SCHEMBL3784396 0.75 FFAR3 (0.32)
SCHEMBL396911 0.74 L3MBTL1 (0.41)
SCHEMBL10527700 0.74 L3MBTL1 (0.41)
SCHEMBL15756822 0.72 DPP4 (0.30)
SCHEMBL25336381 0.71 ARG1 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11992518-B2 Molecular vaccines for infectious disease AGILENT TECHNOLOGIES, INC. (US) 2024-05-28 US disclosed
US-10968269-B1 MHC multimers in borrelia diagnostics and disease AGILENT TECHNOLOGIES, INC. (US) 2021-04-06 US disclosed
US-20210047383-A1 MHC Multimers in Borrelia Diagnostics and Disease DAKO DENMARK APS (DK) 2021-02-18 US disclosed
US-20200347103-A1 MHC MULTIMERS IN TUBERCULOSIS DIAGNOSTICS, VACCINE AND THERAPEUTICS AGILENT TECHNOLOGIES INC (US) 2020-11-05 US disclosed
US-10611818-B2 MHC multimers in tuberculosis diagnostics, vaccine and therapeutics AGILENT TECHNOLOGIES, INC. (US) 2020-04-07 US disclosed
US-20190314471-A1 MOLECULAR VACCINES FOR INFECTIOUS DISEASE AGILENT TECHNOLOGIES, INC. 2019-10-17 US disclosed
US-10369204-B2 Molecular vaccines for infectious disease DAKO DENMARK A/S (DK) 2019-08-06 US disclosed
US-20120258126-A1 Molecular Vaccines for Infectious Disease DAKO DENMARK A/S (DK) 2012-10-11 US disclosed
US-20110318380-A1 MHC Multimers in Cancer Vaccines and Immune Monitoring DAKO DENMARK A/S (DK) 2011-12-29 US disclosed
US-20110236411-A1 MHC Multimers in Tuberculosis Diagnostics, Vaccine and Therapeutics DAKO DENMARK A/S (DE) 2011-09-29 US disclosed
EP-2337795-A2 MHC MULTIMERS IN CANCER VACCINES AND IMMUNE MONITORING Dako Denmark A/S (DK) 2011-06-29 EP disclosed
EP-2254592-A2 MHC MULTIMERS IN BORRELIA DIAGNOSTICS AND DISEASE Dako Denmark A/S (DK) 2010-12-01 EP disclosed
EP-2197908-A2 MHC MULTIMERS IN TUBERCULOSIS DIAGNOSTICS, VACCINE AND THERAPEUTICS Dako Denmark A/S (DK) 2010-06-23 EP disclosed
WO-2010037402-A1 MOLECULAR VACCINES FOR INFECTIOUS DISEASE DAKO DENMARK A/S (DK) 2010-04-08 WO disclosed
WO-2010037395-A2 MHC MULTIMERS IN CANCER VACCINES AND IMMUNE MONITORING DAKO DENMARK A/S (DK) 2010-04-08 WO disclosed
WO-2010037397-A1 MHC MULTIMERS IN CMV IMMUNE MONITORING DAKO DENMARK A/S (DK) 2010-04-08 WO disclosed
WO-2009106073-A2 MHC MULTIMERS IN BORRELIA DIAGNOSTICS AND DISEASE DAKO DENMARK A/S (DK) 2009-09-03 WO disclosed
WO-2009039854-A2 MHC MULTIMERS IN TUBERCULOSIS DIAGNOSTICS, VACCINE AND THERAPEUTICS DAKO DENMARK A/S (DK) 2009-04-02 WO disclosed